| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -6.1 | -5.5 |
| EPS (diluted, $ a share) | $-0.48 | $-0.59 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: TVRD. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Tvardi Therapeutics, Inc.: key numbers
- Share price
- $1.10Close, Nov 16
- Market cap
- $14.7M
- Shares outstanding
- 13.36MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Tvardi Therapeutics, Inc.
All →Tvardi Therapeutics Financial Results
Tvardi Therapeutics reported third quarter 2026 financial results and provided updates on its STAT3 inhibitor pipeline, including plans to advance TTI-109 into clinical development for ulcerative colitis in 2027. The company also confirmed it expects a topline readout for its Phase 1b/2 study of TTI-101 in hepatocellular carcinoma in early Q1 2027.
- Term
- Q3 2026
“We continue to make meaningful progress across our pipeline. Positive Phase 1 results for TTI-109 have strengthened our confidence in its potential as we prepare to advance this next-generation STAT3 inhibitor into clinical development in ulcerative colitis and potentially other inflammatory bowel diseases in 2027, subject to the availability of additional funding. In HCC, we remain encouraged by the previously reported interim results for TTI-101 and look forward to the topline readout in early first quarter of 2027, which will help inform our next steps.”
Imran Alibhai, Ph.D., Chief Executive Officer of Tvardi